Stocks · Healthcare · Medical - Diagnostics & Research
CareDx, Inc CDNA
$67.15 +1.39% Close, Oct 2, 2026 · NASDAQ · Market cap $3.47B
Strong growthStrong trend
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $2.07, up 103.1% year over year.
- Operating margin narrowed to -0.9% from 13.3% a year earlier.
- Over the past year the stock returned +347.7%, ahead of the S&P 500 by 332.6 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 23%
- EPS growth (TTM, YoY)Top 12%
- FCF growth (TTM, YoY)Top 3%
- Revenue growth, 3-year CAGRBottom 40%
- Revenue growth accelerationTop 10%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 33%
- Gross marginTop 42%
- Operating marginTop 43%
- Cash conversion (OCF / net income)Bottom 19%
- Accruals (lower is better)Bottom 11%
- Net debt / EBITDA (lower is better)Top 3%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 17%
- Free-cash-flow yieldTop 28%
- EBITDA / enterprise valueTop 36%
- Sales / enterprise valueBottom 39%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 5%
- 6-month returnTop 1%
- 1-year return vs S&P 500Top 3%
- Distance from 52-week highTop 3%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 19%
- Share of analysts rating BuyTop 50%
- Upside to consensus price targetBottom 7%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 17%
- Maximum drawdown, 3 yearsTop 43%
- Beta vs S&P 500 (lower is better)Top 39%
- Net debt / EBITDA (lower is better)Top 3%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 19.2% | 34.4% | ↑ |
| EPS growth (YoY) | -114.6% | 103.1% | ↑ |
| Gross margin | 66.9% | 70.6% | ↑ |
| Operating margin | 13.3% | -0.9% | ↓ |
| FCF margin | 3.5% | 18.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 34.4% | 19.2% | ↑ | Top 23% |
| EPS growth (TTM, YoY) | 103.1% | -114.6% | ↑ | Top 12% |
| Gross margin | 70.6% | 66.9% | ↑ | Top 42% |
| Operating margin | -0.9% | 13.3% | ↓ | Top 43% |
| Net margin | 24.2% | 15.2% | ↑ | — |
| Free-cash-flow margin | 18.6% | 3.5% | ↑ | — |
| Return on invested capital | -0.9% | — | Top 33% | |
| Revenue growth, 3-year CAGR | 5.7% | — | Bottom 40% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.84×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 3.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -83.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -22.78×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.93%
- Shareholder yield
- 0.93%
- Share count change, 1 year
- -1.6%
- Share count change, 3-year CAGR
- -0.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 4
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +0.7%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $62.25
- Target vs current price
- -7.3%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 77%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 30, 2026 | +59.4% | +7.6% | +28.5% | +43.9% | — |
| Apr 28, 2026 | +209.1% | +0.3% | -4.1% | -1.4% | +72.1% |
| Feb 24, 2026 | +503.0% | +2.4% | -0.2% | -6.5% | +9.3% |
| Nov 4, 2025 | +138.9% | -1.7% | +13.1% | +18.1% | +39.1% |
| Aug 6, 2025 | -66.0% | +1.9% | -3.0% | -0.9% | +11.1% |
| Apr 30, 2025 | +8.1% | -6.9% | -21.8% | -3.1% | -29.5% |
| Feb 26, 2025 | +260.0% | +1.0% | -2.8% | -8.7% | -18.4% |
| Nov 4, 2024 | +156.9% | +1.3% | +4.5% | +13.3% | +2.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | $0.37 | $0.23 | +59.4% | $131.9M |
| Apr 28, 2026 | $0.34 | $0.11 | +209.1% | $117.7M |
| Feb 24, 2026 | $0.12 | $0.02 | +503.0% | $108.4M |
| Nov 4, 2025 | $0.03 | -$0.08 | +138.9% | $100.1M |
| Aug 6, 2025 | -$0.16 | -$0.10 | -66.0% | $86.7M |
| Apr 30, 2025 | -$0.19 | -$0.21 | +8.1% | $84.7M |
| Feb 26, 2025 | $0.18 | $0.05 | +260.0% | $86.6M |
| Nov 4, 2024 | $0.14 | -$0.25 | +156.9% | $82.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 32.4× | — | — | Top 17% |
| P/E (forward) | 56.1× | — | — | — |
| EV / EBITDA | 200.5× | — | — | Top 36% |
| EV / Sales | 6.81× | — | — | Bottom 39% |
| Free-cash-flow yield | 2.45% | — | — | Top 28% |
| Earnings yield | 3.08% | — | — | Top 17% |
P/E over the past five years
Range 12.2× – 24.6× since Dec 31, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +347.7%
- Earnings per share growth (TTM)
- +103.1%
- Change in P/E multiple
- -25.2%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 118
- Days above the 200-day average
- 121
- 50-day average slope (20 days)
- +24.8%
- 200-day average slope (20 days)
- +15.6%
- Distance from 50-day average
- +33.6%
- Distance from 200-day average
- +133.5%
- RSI (14)
- 81.3
- Relative volume
- 1.21×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 82.0%
- Volatility vs own 5-year history
- 62th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.94
- Correlation with S&P 500
- 0.20
- Current drawdown from 1-year high
- +0.0%
- Maximum drawdown, 3 years
- -66.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 20, 2021 | Oct 25, 2023 | -94.9% | 696 days | Not yet recovered |
| Oct 9, 2020 | Nov 2, 2020 | -11.1% | 16 days | 3 days (Nov 5, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.47B
- P/E (TTM)
- 32.4
- EPS, diluted (TTM)
- $2.07
- Revenue (TTM)
- $458.1M
- 52-week range
- $13.95 – $69.80
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $296.4M | $321.8M | $280.3M | $333.8M | $379.8M |
| Gross profit | $199.0M | $209.6M | $178.3M | $224.2M | $256.6M |
| Operating income | -$29.7M | -$77.2M | -$203.4M | $40.8M | -$25.1M |
| Net income | -$30.7M | -$76.6M | -$190.3M | $52.5M | -$21.4M |
| EPS (diluted) | -$0.59 | -$1.44 | -$3.54 | $0.93 | -$0.40 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $82.9M | $86.6M | $84.7M | $86.7M | $100.1M | $108.4M | $117.7M | $131.9M |
| Net income | -$7.4M | $78.0M | -$10.4M | -$8.6M | $1.7M | -$4.1M | $2.8M | $110.6M |
| EPS (diluted) | -$0.14 | $1.51 | -$0.19 | -$0.16 | $0.03 | -$0.08 | $0.05 | $2.07 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$19.3M | -$25.2M | -$18.4M | $38.0M | $42.0M |
| Capital expenditure | -$20.3M | -$24.3M | -$9.2M | -$6.5M | -$5.9M |
| Free cash flow | -$39.6M | -$49.6M | -$27.6M | $31.6M | $36.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $188.9M | -$642,000 | -$27.5M | -$522,000 | -$79.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $373.6M
- Total assets
- $533.0M
- Total liabilities
- $107.4M
- Total debt
- $19.2M
- Net debt
- -$354.4M
- Shareholders’ equity
- $425.6M
As of Jun 30, 2026 (filed Jul 30, 2026).
Short interest
- Shares sold short
- 6,297,191
- Days to cover
- 6.29
- Change vs previous report
- +8.0%
FINRA short interest, settlement date Sep 15, 2026.